Atria Investments LLC acquired a new stake in shares of Chemed Corp. (NYSE:CHE) in the 1st quarter, Holdings Channel reports. The firm acquired 1,141 shares of the company’s stock, valued at approximately $311,000.
A number of other hedge funds and other institutional investors have also made changes to their positions in CHE. Eaton Vance Management acquired a new stake in Chemed during the 4th quarter valued at approximately $19,967,000. BlackRock Inc. lifted its stake in Chemed by 2.4% during the 4th quarter. BlackRock Inc. now owns 2,079,274 shares of the company’s stock valued at $505,307,000 after acquiring an additional 49,135 shares during the period. Assenagon Asset Management S.A. purchased a new position in shares of Chemed during the 4th quarter valued at approximately $9,296,000. Goldman Sachs Group Inc. increased its holdings in shares of Chemed by 70.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 72,500 shares of the company’s stock valued at $17,619,000 after purchasing an additional 29,844 shares in the last quarter. Finally, WINTON GROUP Ltd purchased a new position in shares of Chemed during the 4th quarter valued at approximately $6,320,000. Institutional investors and hedge funds own 95.54% of the company’s stock.
Get Chemed alerts:
Several equities analysts have recently weighed in on CHE shares. Royal Bank of Canada reaffirmed a “hold” rating and set a $258.00 target price on shares of Chemed in a report on Friday, February 16th. ValuEngine raised shares of Chemed from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Oppenheimer lifted their target price on shares of Chemed from $270.00 to $275.00 and gave the company an “outperform” rating in a report on Friday, February 16th. Finally, Zacks Investment Research raised shares of Chemed from a “hold” rating to a “buy” rating and set a $339.00 target price for the company in a report on Tuesday, April 24th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $290.67.
Chemed opened at $328.00 on Tuesday, MarketBeat.com reports. The company has a quick ratio of 0.88, a current ratio of 0.91 and a debt-to-equity ratio of 0.26. The company has a market cap of $5.26 billion, a PE ratio of 61.19, a PEG ratio of 3.01 and a beta of 1.04. Chemed Corp. has a 1-year low of $326.52 and a 1-year high of $331.30.
Chemed (NYSE:CHE) last posted its earnings results on Thursday, April 19th. The company reported $2.72 earnings per share for the quarter, beating the consensus estimate of $2.36 by $0.36. The firm had revenue of $439.18 million during the quarter, compared to analyst estimates of $419.33 million. Chemed had a net margin of 6.67% and a return on equity of 33.05%. The business’s quarterly revenue was up 8.2% on a year-over-year basis. During the same period in the previous year, the firm earned $1.82 EPS. analysts expect that Chemed Corp. will post 10.96 earnings per share for the current fiscal year.
Chemed announced that its Board of Directors has approved a stock repurchase program on Tuesday, March 6th that authorizes the company to repurchase $150.00 million in shares. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Shares repurchase programs are often an indication that the company’s board believes its shares are undervalued.
In related news, VP Naomi C. Dallob sold 1,050 shares of the business’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $257.00, for a total value of $269,850.00. Following the completion of the sale, the vice president now owns 6,649 shares of the company’s stock, valued at approximately $1,708,793. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO David Patrick Williams sold 10,000 shares of the business’s stock in a transaction on Tuesday, April 24th. The stock was sold at an average price of $301.11, for a total transaction of $3,011,100.00. Following the completion of the sale, the chief financial officer now directly owns 75,052 shares of the company’s stock, valued at approximately $22,598,907.72. The disclosure for this sale can be found here. In the last three months, insiders sold 82,421 shares of company stock valued at $25,195,501. 4.82% of the stock is owned by insiders.
Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corp. (NYSE:CHE).